MMP-9 -1562C/T基因多态性与2型糖尿病肾病的关系研究

• 论著 •

MMP-9 -1562C/T基因多态性与2型糖尿病肾病的关系研究

潘明麟¹,田刚²,张晓梅¹,孙卫华¹,徐浣白¹,时照明¹

1. 蚌埠医学院第一附属医院内分泌科
2. 天津市公安医院检验科

收稿日期:2009-08-31 修回日期:2010-04-29 出版日期:2010-08-15 发布日期:2010-08-15
通讯作者: 田刚

Study on the association of the matrix metalloproteinase-9 gene -1562C/T polymorphism with diabetic nephropathy

Received:2009-08-31 Revised:2010-04-29 Published:2010-08-15 Online:2010-08-15

潘明麟1 ,田刚2 ,张晓梅1 ,孙卫华1 ,徐浣白1 ,时照明1 . MMP-9 -1562C/T基因多态性与2型糖尿病肾病的关系研究[J]. .

摘要/Abstract

摘要： 摘要目的：探讨2型糖尿病（T2DM）患者基质金属蛋白酶-9基因-1562C/T（MMP-9 -1562C/T）多态性与糖尿病肾病（DN）的关系以及与DN不同病期的相关性。方法：将150例T2DM患者按DN诊断标准分为DN组与非肾病（NDN）组，DN组分为微量白蛋白尿期、临床白蛋白尿期和肾功能不全期。另择52例健康人作为正常对照（NC）组。应用限制性片段长度多态性分析各组基因型。结果：DN组的HbA1c、SBP、Cr、BUN、UAER值高于NDN、NC组（P<0.01）。DN组分别和NDN组、NC组之间基因型分布差别均有统计学意义（P<0.01）。T2DM中CC、CT、TT各基因型DN发病率递减，分别为59.7%、56.7%、34.9%。C和T等位基因DN发病率分别为59.2%、40.5%，携T等位基因者发生DN的风险是携C等位基因者的0.47倍（P<0.01，95%CI 0.29～0.75）；DN组内3期TT基因型与T等位基因频率随肾功能降低而递减；结论：MMP-9 -1562C/T基因多态性与DN发生有关，T等位基因是DN患者的保护基因。

关键词: 基质金属蛋白酶-9, 基因多态性, 糖尿病肾病

Abstract: Abstract Objective: To explore the dependability of matrix metalloproteinase-9 (MMP-9) gene -1562C/T and diabetic nephropathy (DN), and the relationship with different stage of DN. Methods: 150 type 2 diabetes (T2DM) patients were divided into DN group and diabetes without DN (NDN) group. DN group included microamount albuminuria, clinical alubuminuria and renal inadequacy stage. 52 healthy people were selected as normal control (NC) group. The genotypes were assessed by restriction fragment length polymorphism．Results: The average HbA1c、SBP、Cr、BUN、UAER of DN group were significantly higher than that of NDN or NC group (P<0.01).There was significant difference in frequencies of allele or genotype of polymorphismC/T between three groups (P<0.01). DN incidence rate in type 2 diabetics containing with genotype of CC, CT or TT respectively were decreased gradually. DN incidence rate containing with allele C and T were 59.2% and 40.5% respectively. The T allele carriers had 0.47 times risk for increased incidence of DN compared with that of C allele carriers (P<0.01，95%CI 0.29～0.75). The frequencies of TT genotype and T allele in three stages of DN decrease with renal hypofunction. Conclusion: The polymorphism of MMP-9 -1562C/T is associated with the development of DN, T allele is the protective gene of DN.

Key words: matrix metalloproteinase-9, gene polymorphism, diabetic nephropathy

[1]	侯维玲, 乔云阳, 吴小芸, 施会敏, 曲高婷, 张爱青. 锌指蛋白281抑制高糖诱导的肾小管上皮细胞上皮间质转化和细胞外基质合成[J]. 天津医药, 2024, 52(7): 720-726.
[2]	王娴, 刘霞明, 陈曼玉, 赵君, 王立东. 基于机器学习对2型糖尿病肾病预测模型的构建及验证[J]. 天津医药, 2024, 52(7): 775-780.
[3]	夏雨薇, 乔云阳, 刘雪薇, 施会敏, 曲高婷, 张爱青, 甘卫华. tRF-1:30对高糖诱导的肾小管上皮细胞炎性因子表达的影响[J]. 天津医药, 2024, 52(6): 561-566.
[4]	谷巍, 张惠娜, 侯丽萍, 于敏, 程黎蓉. 脂质相关指数与糖尿病肾病相关性研究[J]. 天津医药, 2024, 52(12): 1308-1312.
[5]	杨娟, 张厚芬, 吴松, 陈莹, 罗华荣. LncRNA OIP5-AS1调节miR-25-3p/SOX4轴对高糖诱导的人肾小管上皮细胞生物学过程的影响[J]. 天津医药, 2023, 51(2): 131-138.
[6]	许莉敏, 谢燕. 外周血单核细胞DNMT1及血清IL-6在糖尿病肾脏病中的表达及意义[J]. 天津医药, 2023, 51(2): 194-197.
[7]	陈宇, 黄国东, 覃婷, 张泽朝, 沈小楠, 许艺镡, 刘少芳. miRNA-21在糖尿病肾脏病的作用机制及中药干预新进展[J]. 天津医药, 2023, 51(12): 1387-1392.
[8]	姜赫, 刘武, 吕纯懿, 张诏. 环状RNA在糖尿病肾病中的研究进展[J]. 天津医药, 2022, 50(7): 780-784.
[9]	陈灵芝, 钟开义, 陈立国. MTHFR基因启动子甲基化与糖尿病肾病发病的关系研究[J]. 天津医药, 2022, 50(6): 633-638.
[10]	曹磊, 胡恩赑, 李晓楠. vWF和vWF裂解酶水平对糖尿病肾病的影响[J]. 天津医药, 2022, 50(2): 190-194.
[11]	吴玮熙, 刘帅辉, 周赛君, 刘红岩, 张睿, 于珮. 高糖通过miR-192调控CAV-1/EGF影响肾小球系膜细胞增殖、迁移及细胞外基质形成的机制研究[J]. 天津医药, 2022, 50(10): 1020-1025.
[12]	韩敬, 顾津伊, 聂君旭, 张艳萍, 赵玲华. 2型糖尿病肾病患者血清miR-27b-3p、miR-342-3p表达特点及临床意义[J]. 天津医药, 2022, 50(10): 1077-1082.
[13]	姜莹莹, 王靖宇, 孔岩, 王颖, 程静丽, 王珊珊, 单春艳△. 中性粒细胞/淋巴细胞比值与2型糖尿病患者肾小管损伤的相关性研究[J]. 天津医药, 2022, 50(1): 83-87.
[14]	郭哲李姗陈焕丽. 糖尿病肾病患者血清HMGA2蛋白表达及其与肾功能进展的关系[J]. 天津医药, 2021, 49(5): 509-513.
[15]	张颖超, 米焱, 王彩丽. 骨形态发生蛋白-7参与糖尿病肾病发病机制的研究进展[J]. 天津医药, 2021, 49(10): 1107-1111.